Description of a Murine Model of Pneumocystis Pneumonia.
Pneumocystis pneumonia
Pneumocystis spp.
Infectious challenge
Murine model
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
10
10
2023
accepted:
19
03
2024
medline:
6
5
2024
pubmed:
6
5
2024
entrez:
6
5
2024
Statut:
epublish
Résumé
Pneumocystis pneumonia is a serious lung infection caused by an original ubiquitous fungus with opportunistic behavior, referred to as Pneumocystis jirovecii. P. jirovecii is the second most common fungal agent among invasive fungal infections after Candida spp. Unfortunately, there is still an inability to culture P. jirovecii in vitro, and so a great impairment to improve knowledge on the pathogenesis of Pneumocystis pneumonia. In this context, animal models have a high value to address complex interplay between Pneumocystis and the components of the host immune system. Here, we propose a protocol for a murine model of Pneumocystis pneumonia. Animals become susceptible to Pneumocystis by acquiring an immunocompromised status induced by iterative administration of steroids within drinking water. Thereafter, the experimental infection is completed by an intranasal challenge with homogenates of mouse lungs containing Pneumocystis murina. The onset of clinical signs occurs within 5 weeks following the infectious challenge and immunosuppression can then be withdrawn. At termination, lungs and bronchoalveolar lavage (BAL) fluids from infected mice are analyzed for fungal load (qPCR) and immune response (flow cytometry and biochemical assays). The model is a useful tool in studies focusing on immune responses initiated after the establishment of Pneumocystis pneumonia.
Identifiants
pubmed: 38709375
doi: 10.1007/s11046-024-00846-1
pii: 10.1007/s11046-024-00846-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Subventions
Organisme : Région Centre Val de Loire grant
ID : Project APR-IA FLUKILLER
Organisme : Agence Nationale de la Recherche
ID : ANR-21-CO16-0001-01
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–98.
doi: 10.1056/NEJMra032588
pubmed: 15190141
Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127(1242):e11-17.
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi (Basel). 2017;3:57.
doi: 10.3390/jof3040057
pubmed: 29371573
Li M-C, Lee N-Y, Lee C-C, Lee H-C, Chang C-M, Ko W-C. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect. 2014;47:42–7.
doi: 10.1016/j.jmii.2012.08.024
pubmed: 23063081
Wasserman S, Engel ME, Griesel R, Mendelson M. Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:482.
doi: 10.1186/s12879-016-1809-3
pubmed: 27612639
pmcid: 5018169
Cushion MT, Tisdale-Macioce N, Sayson SG, Porollo A. The persistent challenge of pneumocystis growth outside the mammalian lung: past and future approaches. Front Microbiol. 2021;12:681474.
doi: 10.3389/fmicb.2021.681474
pubmed: 34093506
pmcid: 8174303
Chesnay A, Paget C, Heuzé-Vourc’h N, Baranek T, Desoubeaux G. Pneumocystis pneumonia: pitfalls and hindrances to establishing a reliable animal model. J Fungi (Basel). 2022;8:129.
doi: 10.3390/jof8020129
pubmed: 35205883
Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am J Pathol. 1990;136:1173–86.
pubmed: 2349968
pmcid: 1877432
Elsegeiny W, Zheng M, Eddens T, Gallo RL, Dai G, Trevejo-Nunez G, et al. Murine models of Pneumocystis infection recapitulate human primary immune disorders. JCI Insight. 2018;3:e91894.
doi: 10.1172/jci.insight.91894
pubmed: 29925696
pmcid: 6124425
Khalife S, Chabé M, Gantois N, Audebert C, Pottier M, Hlais S, et al. Relationship between Pneumocystis carinii burden and the degree of host immunosuppression in an airborne transmission experimental model. J Eukaryot Microbiol. 2016;63:309–17.
doi: 10.1111/jeu.12280
pubmed: 26509699
Magnen M, Gueugnon F, Petit-Courty A, Baranek T, Sizaret D, Brewah YA, et al. Tissue kallikrein regulates alveolar macrophage apoptosis early in influenza virus infection. Am J Physiol Lung Cell Mol Physiol. 2019;316:L1127–40.
doi: 10.1152/ajplung.00379.2018
pubmed: 30908937
Baranek T, Morello E, Valayer A, Aimar R-F, Bréa D, Henry C, et al. FHL2 regulates natural killer cell development and activation during streptococcus pneumoniae infection. Front Immunol. 2017. https://doi.org/10.3389/fimmu.2017.00123 .
doi: 10.3389/fimmu.2017.00123
pubmed: 28243234
pmcid: 5303898
Hassane M, Jouan Y, Creusat F, Soulard D, Boisseau C, Gonzalez L, et al. Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response. Mucosal Immunol. 2020;13:128–39.
doi: 10.1038/s41385-019-0212-y
pubmed: 31628425
Desoubeaux G, Franck-Martel C, Caille A, Drillaud N, Carluer L, de Kyvon M-A, Bailly É, et al. Use of calcofluor-blue brightener for the diagnosis of Pneumocystis jirovecii pneumonia in bronchial-alveolar lavage fluids: a single-center prospective study. Med Mycol. 2017;55:295–301.
pubmed: 27562860
Bailly E, Debieu E, Franck-Martel C, Desoubeaux G, Chandenier J. Extraction d’ADN de Pneumocystis jirovecii à l’aide de la trousse MycoGENIE
doi: 10.1016/j.mycmed.2015.06.036
Zheng M, Shellito JE, Marrero L, Zhong Q, Julian S, Ye P, et al. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest. 2001;108:1469–74.
doi: 10.1172/JCI13826
pubmed: 11714738
pmcid: 209424
Sanchez CA, Chabé M, Aliouat EM, Durand-Joly I, Gantois N, Conseil V, et al. Exploring transplacental transmission of Pneumocystis oryctolagi in first-time pregnant and multiparous rabbit does. Med Mycol. 2007;45:701–7.
doi: 10.1080/13693780701531156
pubmed: 18027254
Bienvenu A-L, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis. 2016;46:11–7.
doi: 10.1016/j.ijid.2016.03.018
pubmed: 27021532
Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50:600–13.
pubmed: 22330705
pmcid: 3189662
Powles MA, McFadden DC, Pittarelli LA, Schmatz DM. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect Immun. 1992;60:1397–400.
doi: 10.1128/iai.60.4.1397-1400.1992
pubmed: 1548065
pmcid: 257010
Ripamonti C, Bishop LR, Kovacs JA. Pulmonary Interleukin-17-positive lymphocytes increase during Pneumocystis murina Infection but are not required for clearance of pneumocystis. Infect Immun. 2017. https://doi.org/10.1128/IAI.00434-16 .
doi: 10.1128/IAI.00434-16
pubmed: 28438973
pmcid: 5478948
Benfield TL, Kharazmi A, Larsen CG, Lundgren JD. Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with AIDS-associated Pneumocystis carinii pneumonia. Scand J Infect Dis. 1997;29:367–71.
doi: 10.3109/00365549709011832
pubmed: 9360251
Swain SD, Wright TW, Degel PM, Gigliotti F, Harmsen AG. Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice. Infect Immun. 2004;72:5722–32.
doi: 10.1128/IAI.72.10.5722-5732.2004
pubmed: 15385471
pmcid: 517543
Linke M, Ashbaugh A, Demland J, Koch J, Tanaka R, Walzer P. Resolution of Pneumocystis murina infection following withdrawal of corticosteroid induced immunosuppression. Microb Pathog. 2006;40:15–22.
doi: 10.1016/j.micpath.2005.10.002
pubmed: 16321497
Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:223–31.
doi: 10.7326/0003-4819-111-3-223
pubmed: 2546472
Shellito JE, Tate C, Ruan S, Kolls J. Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii. J Infect Dis. 2000;181:2011–7.
doi: 10.1086/315487
pubmed: 10837183
Zhang N-N, Huang X, Feng H-Y, Huang L-N, Xia J-G, Wang Y, et al. Circulating and pulmonary T-cell populations driving the immune response in non-HIV immunocompromised patients with Pneumocystis jirovecii Pneumonia. Int J Med Sci. 2019;16:1221–30.
doi: 10.7150/ijms.34512
pubmed: 31588187
pmcid: 6775264
Thomas CF, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5:298–308.
doi: 10.1038/nrmicro1621
pubmed: 17363968
Chou C-W, Lin F-C, Tsai H-C, Chang S-C. The importance of pro-inflammatory and anti-inflammatory cytokines in Pneumocystis jirovecii pneumonia. Med Mycol. 2013;51:704–12.
doi: 10.3109/13693786.2013.772689
pubmed: 23488973